City of Hope
↗Duarte, California, USA
City of Hope is a world-renowned independent research and treatment center for cancer, diabetes, and other life-threatening diseases. Founded in 1913, it is one of only 57 National Cancer Institute-designated comprehensive cancer centers in the United States and a founding member of the National Comprehensive Cancer Network (NCCN). The organization is uniquely integrated, combining a world-class hospital system with the Beckman Research Institute and a graduate school of biological sciences.
The institution is a pioneer in biotechnology, having developed the technology that led to the first synthetic human insulin and several breakthrough cancer drugs, including Herceptin, Rituxan, and Avastin. Following its 2022 acquisition of Cancer Treatment Centers of America, City of Hope has expanded into a national system with clinical locations across California, Arizona, Illinois, and Georgia, operating as one of the largest oncology-focused healthcare and research organizations in the country.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology and Diabetes Research
SIZE & FINANCIALS
Employees:10000+
Revenue:$2B-$5B
Founded:1913
Ownership:nonprofit
Status:operating
FUNDING
Stage:N/A
Total Raised:$4.8B (Annual Operating Budget)
Investors:National Institutes of Health (NIH), California Institute for Regenerative Medicine (CIRM), National Cancer Institute (NCI), Wanek Family Project, Stephenson Family (Tessa Stephenson Brand and A. Emmet Stephenson Jr.)
PIPELINE
Stage:Commercial
Lead Drug Stage:Phase 3 (Collaborative assets)
Modalities:Cell therapy, CAR-T, Monoclonal antibodies (mAb), Small molecule, ADC, Gene therapy, Islet cell transplantation
Active Trials:400
Trial Phases:Phase 1: 150 | Phase 2: 200 | Phase 3: 50 | Phase 4: 10
FDA Approvals:5
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:City of Hope
Subsidiaries:Beckman Research Institute, Translational Genomics Research Institute (TGen), AccessHope, City of Hope Medical Group, City of Hope Phoenix (formerly CTCA), City of Hope Atlanta (formerly CTCA), City of Hope Chicago (formerly CTCA)
Key Partnerships:Amgen (CodeBreaK trials), RLL LLC (Exclusive license for AOH1996), Scopus BioPharma (STAT3 gene therapy), Cizzle Biotech (Liquid biopsy for lung cancer), National Cancer Institute (NCI)
COMPETITION
Position:Leader
Competitors:MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, Fred Hutchinson Cancer Center
LEADERSHIP
Key Executives:
Robert W. Stone - CEO
John D. Carpten, Ph.D. - Chief Scientific Officer
Marcel van den Brink, M.D., Ph.D. - President, City of Hope Los Angeles
Scientific Founders:Samuel H. Golter (Historical Leader), Arthur D. Riggs (Co-developer of synthetic insulin)
Board Members:Matthew Hobart (Co-Managing Partner, TPG Growth), Stephanie S. Okey (Former SVP, Genzyme), Ronald L. Sargent (Former CEO, Staples), Suzanne Vautrinot (Major General, USAF Ret.)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with City of Hope. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.